en ENGLISH
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Kontakt Zasady publikacji prac Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

3/2020
vol. 95
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Opis przypadku

Gordon syndrome in an 11-year-old boy: long-term follow-up

Andrzej Badeński
1
,
Marta Badeńska
1
,
Omar Bjanid
1
,
Justyna Czubilińska-Łada
1
,
Aleksandra Gliwińska
1
,
Anna Bogdał
2
,
Olga Kupczyk
3
,
Maria Szczepańska
1

1.
Chair and Department of Paediatrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
2.
Department of Paediatrics, District Hospital in Zawiercie, Poland
3.
Department of Paediatric Nephrology with Dialysis Division for Children, Independent Public Clinical Hospital No. 1, Zabrze, Poland
Pediatr Pol 2020; 95 (3): 184–190
DOI: https://doi.org/10.5114/polp.2020.100877
Data publikacji online: 2020/10/30
Plik artykułu:
- Gordon syndrome.pdf  [0.35 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Baumgartner H, Bonhoeffer P, Westby J. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2915-2957.
2. Paver W, Pauline G. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust 1964; 2: 305-306.
3. Gordon RD, Geddes RA, Pawsey CG, O’Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970; 19: 287-294.
4. Mayan H, Vered I, Mouallem M, et al. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002; 87: 3248-3254.
5. Gordon RD, Hodsman GP. The syndrome of hypertension and hyperkalaemia without renal failure: long term correction by thiazide diuretic. Scott Med J 1986; 31: 43-44.
6. Toka HR, Koshy JM, Hariri A. The molecular basis of blood pressure variation. Pediatr Nephrol 2013; 28: 387-399.
7. Gordon RD. Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 1986; 8: 93-102.
8. Mayan H, Munter G, Shaharabany M, et al. Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: description of a large family with the Q565E WNK4 mutation. J Clin Endocrin Metabol 2004; 89: 4025-4030.
9. Mayan H, Vered I, Mouallem M, et al. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrin Metab 2002; 87: 3248-3254.
10. Gamba G. Role of WNK kinases in regulating tubular salt and potassium transport and in the development of hypertension. Am J Physiol 2005; 288: F245-F252.
11. Margolis BL, Lifschitz MD. The Spitzer-Weinstein syndrome: one form of type IV renal tubular acidosis and its response to hydrochlorothiazide. Am J Kidney Dis 1986; 7: 241-244.
12. Spitzer A, Edelmann CM Jr, Goldberg LD, Henneman PH. Short stature, hyperkalemia and acidosis: a defect in renal transport of potassium. Kidney Int 1973; 3: 251-257.
13. Weinstein SF, Allan DM, Mendoza SA. Hyperkalemia, acidosis, and short stature associated with a defect in renal potassium excretion. J Pediatr 1974; 85: 355-358.
14. Ellison DH. Pseudohypoaldosteronism Type II. 2011 Nov 10 [Updated 2017 Feb 16]. In: GeneReviews® [Internet], Adam MP, Ardinger HH, Pagon RA, et al. (eds.). University of Washington, Seattle 1993-2020.
15. Riepe FG. Clinical and molecular features of type 1 pseudohypoaldosteronism. Horm Res 2009; 72: 1-9.
16. Hadchouel J, Ellison DH, Gamba G. Regulation of renal electrolyte transport by WNK and SPAK-OSR1 kinases. Annu Rev Physiol 2016; 78: 367-389.
17. Boyden LM, Choi M, Choate KA, et al. Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 2012; 482: 98-102.
18. Louis-Dit-Picard H, Barc J, Trujillano D, et al. KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet 2012; 44: 456-460, S451-453.
19. Hollander R, Mortier G, van Hoeck K. Hyperkalemia in young children: blood pressure checked? Euro J Pediatr 2016; 175: 2011-2013.
20. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of hypertension. Circ Res 2015; 116: 937-959.
21. O’Shaughnessy KM. Gordon Syndrome: a continuing story. Pediatr Nephrol 2015; 30: 1903-1908.
22. Vehaskari VM. Heritable forms of hypertension. Pediatr Nephrol 2009; 24: 1929-1937.
Copyright: © 2020 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.